September 25, 2006
Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotechnology industries, today announced expanded capabilities in the area of pricing for pharmaceutical and biotech clients.
“Over the years, we have built extensive experience in pricing-related work. We haven’t actively sought that business, simply because our clients have repeatedly reached out to us, asking for help in developing pricing and contracting strategies. Now, however, we are announcing and promoting a formalized service offering,” stated John Campbell,
“In our experience, companies are beginning to build pricing strategies much earlier in product development, and they are taking much more of a cross-functional approach, involving professionals in new product planning, marketing, access and reimbursement, contracting, and so on. Our Managed Markets and Brand Management practices combine expertise in all of those functions and have in-depth understanding of key therapeutic areas, including oncology, CNS, GI, and cardiovascular. It’s that combination that sets us apart from other firms providing services in this space,” added
Campbell Alliance has developed sophisticated research, modeling, and scenario planning techniques to estimate the impact of price on market access, reimbursement, and utilization, as well as to develop detailed payer contracting strategies. The firm has extensive pricing experience at the product and portfolio levels, including helping clients determine the optimum list price and net price for new products, as well as develop pricing strategies for in-line products with new indications.
“Our true differentiator from competing firms is our ability to optimize the pricing equation across the payer, physician, and patient channels, including how pricing and formulary access affect key decisions,” said Kevin Barnett, Senior Vice President and leader of the firm’s Managed Markets Practice.